Skip to content
About
Supporter
Expert Index
Editorial Board
Editorial Team
Editorial Policy
Contact
Sign up
Visit
Home
(current)
Diseases
Parkinson's Disease
Multiple Sclerosis and Related Disorders
Headache
Amyotrophic Lateral Sclerosis
Epilepsy
Sleep Disorders
Stroke
Neuromuscular Disorders
Movement Disorders
View all Diseases
Topics
Biology
Diagnostics
Trial Updates
Treatment
Prevention
Surgery
Imaging
Genetics
COVID-19
View all Topics
Conferences
EAN 2022
ESOC 2022
AAN 2022
CONy 2022
AD/PD 2022
World Sleep 2022
View all Conferences
Features
Podcasts
About
Supporter
Expert Index
Editorial Board
Editorial Team
Editorial Policy
Contact
Sign up
Treatment
2:24
Latest guidelines on anti-CGRP antibodies: first-line and long-term use
Messoud Ashina
• 23 Jun 2022
1:39
Long-term efficacy of adjunctive cenobamate in patients with focal seizures
Christian Brandt
• 14 Jun 2022
1:39
Progressive MS treatment – what is next?
Giancarlo Comi
• 23 Mar 2022
1:32
A personalized approach for neurostimulation
Roi Cohen Kadosh
• 23 Mar 2022
6:51
Methods for measuring treatment response and disease progression in MS
Giancarlo Comi
• 23 Mar 2022
3:58
Neurostimulation to improve cognition in health and disease
Roi Cohen Kadosh
• 23 Mar 2022
1:47
The future of patient-reported outcomes in progressive MS
Giancarlo Comi
• 23 Mar 2022
2:03
Future directions of neurostimulation
Roi Cohen Kadosh
• 23 Mar 2022
3:14
Improving brain waste clearance to treat CAA and Alzheimer’s disease
Roxana Carare
• 4 May 2022
8:00
Unresolved questions on post-stroke anticoagulation in atrial fibrillation
Nils Peters
et al.
• 4 May 2022
22:22
ATTICUS trial of apixaban vs aspirin for secondary prevention after ESUS: findings & implications
Sven Poli
et al.
• 20 May 2022
1:19
Blood-brain barrier disruption increases the risk of hemorrhagic transformation in ischemic stroke
Francesco Arba
• 4 May 2022
1:52
Does bridging thrombolysis impact clot composition?
Rosanna Rossi
• 5 May 2022
5:59
The value of specific reversal agents in stroke management
Senta Frol
• 17 May 2022
3:14
Using DMTs beyond patients with active MS
Xavier Montalban
• 29 Mar 2022
1:46
The clinical benefit of safinamide in treating Parkinson’s disease
Angelo Antonini
• 29 Mar 2022
1
2
3
4
5
…
53
Next